Vertical: CNMBase Year: 2025
Market Size (2025)
$18.11M
Projected (2032)
$27.96M
CAGR (2022–2032)
6.4%
Key Players
10+
Market Overview
The global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone market was valued at USD 18.113 Million in 2025 and is projected to reach USD 27.962 Million by 2032, registering a CAGR of 6.39% during 2026–2032. The market has expanded steadily from USD 14.981 Million in 2022 and is expected to add USD 9.849 Million in absolute value between 2025 and 2032.
2-Chloro-1-(1-chlorocyclopropyl)ethanone (CAS No. 120983-72-4), also referred to as 1-chloro-1-chloroacetylcyclopropane, is a chlorinated cyclopropyl ketone used almost entirely as a key building block in the synthesis of prothioconazole, a broad-spectrum triazolinthione fungicide widely applied on cereals, soybean, oilseed rape and pulses. Demand for the intermediate is therefore closely linked to global prothioconazole technical production, which has moved from a single originator (Bayer) to a large and growing base of generic producers, particularly in China, since the expiry of the core compound patents in 2015 and of later process and crystal-form patents.
Key Findings
By Downstream Product: Prothioconazole is both the largest and the fastest-growing segment, accounting for 85.0% of 2025 market value (USD 15.396 Million) and expanding at a CAGR of 6.70%, compared with 4.45% for the Others segment.
By Purity: The 98% & Above grade led the market with a 80.0% share in 2025 (USD 14.490 Million) and is also the fastest-growing grade, at a CAGR of 6.95%, while the Below 98% grade is projected to grow at 3.92%.
By Region: Asia Pacific is the leading region, with USD 14.128 Million in 2025 (78.0% share). Middle East & Africa is the fastest-growing region, with a CAGR of 8.84%, followed by Latin America at 7.82%.
By Country: China is the leading country market, valued at USD 8.759 Million in 2025 (48.4% of the global market and 62.0% of Asia Pacific). UAE is the fastest-growing country, with a CAGR of 11.00%, followed by Saudi Arabia at 10.85% and India at 8.26%.
Segmentation Summary
The market is analysed by downstream product (Prothioconazole and Others), by purity (98% & Above and Below 98%), and by region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), with country-level analysis for 16 countries and four regional "Rest of" groupings. Prothioconazole synthesis absorbs the large majority of volume, and its share rises from 85.0% in 2025 to 86.8% in 2032. Within purity grades, the 98% & Above grade benefits from the tighter impurity specifications applied to registered prothioconazole technical, raising its share from 80.0% in 2025 to 83.0% in 2032.
Competitive Landscape Summary
The competitive landscape is moderately fragmented and is shaped by the integration strategies of prothioconazole technical producers. Bayer AG, the originator of prothioconazole, manufactures the intermediate captively for its own technical production. In China, a growing group of integrated producers, including Hailir Pesticides and Chemicals Group, Anhui Jiuyi Agriculture, CAC Nantong Chemical (Taihe), ABA Chemicals, Jiangsu Changqing Agrochemical, Yifan Biotechnology Group and Hebei Xingbai, have built or announced prothioconazole technical capacity, several with dedicated intermediate units. ADAMA operates its own prothioconazole production, including a multi-purpose plant in Brazil, while Indian companies such as Hikal hold process know-how and supply prothioconazole technical. Competition centres on cost per tonne, impurity profile, regulatory equivalence with the reference technical, and reliability of supply.
Challenges and Opportunities
The main challenges are the significant capacity additions for prothioconazole technical in China, which have exerted strong downward pressure on technical and intermediate prices; stringent environmental, safety and wastewater requirements for chlorination and cyclisation processes; and regulatory uncertainty linked to the ongoing renewal of prothioconazole in the European Union, where approval has been extended to 31 March 2027. The leading opportunities lie in backward integration into upstream raw materials such as 2-acetyl-γ-butyrolactone, supply of high-purity grades to generic registrants seeking technical equivalence, and growth in fast-expanding agricultural markets in Latin America, South and Southeast Asia, and the Middle East & Africa.
Future Outlook
Over 2026–2032 the market is expected to grow at a CAGR of 6.39%, rising from USD 19.287 Million in 2026 to USD 27.962 Million in 2032. Growth will be supported by expanding prothioconazole use in cereal and soybean disease management, the continued shift of generic technical manufacturing to Asia, and widening registration of prothioconazole-based mixtures. Asia Pacific will remain the production and consumption hub, adding USD 7.808 Million between 2025 and 2032, while Latin America and Middle East & Africa will record the fastest growth from smaller bases.
The 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market market is projected to grow at a CAGR of 6.4% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
2-Chloro-1-(1-chlorocyclopropyl)ethanone (molecular formula C5H6Cl2O; molecular weight approximately 153.0 g/mol; CAS No. 120983-72-4) is an α-chloroketone carrying a 1-chlorocyclopropyl group. It is produced industrially by building the 1-acetyl-1-chlorocyclopropane ring system, typically from 2-acetyl-γ-butyrolactone via chlorinated pentanone intermediates and base-mediated cyclisation under phase-transfer catalysis, followed by α-chlorination of the acetyl group with chlorine or sulfuryl chloride. In the downstream prothioconazole route, the ketone reacts with a 2-chlorobenzyl Grignard reagent to form the corresponding chlorohydrin or oxirane, which is subsequently converted with 1,2,4-triazole derivatives and sulfur to yield prothioconazole.
For the purpose of this study, the market includes the value of 2-chloro-1-(1-chlorocyclopropyl)ethanone sold or transferred for use in the synthesis of prothioconazole and other downstream products, in all purity grades. The market excludes the value of upstream raw materials (such as 2-acetyl-γ-butyrolactone, chlorinated pentanones and chlorinating agents), the downstream oxirane and chlorohydrin intermediates, prothioconazole technical, and formulated fungicide products.
Scope of the Study
The study covers the global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone market, segmented as follows:
By Downstream Product: Prothioconazole; Others
By Purity: 98% & Above; Below 98%
By Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA)
Timeline: Historic years 2022–2024; base year 2025; forecast period 2026–2032
Currency: All market values are presented in USD Million
Research Objectives
To estimate and forecast the size of the global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone market in value terms (USD Million) for 2022–2032.
To analyse the market by downstream product and by purity, and to assess the relative attractiveness of each segment.
To quantify the market across five regions and their constituent countries, and to identify the leading and fastest-growing geographies.
To examine the link between prothioconazole technical capacity additions, particularly in China and India, and demand for the intermediate.
To evaluate the drivers, restraints, opportunities, trends and challenges shaping the market, including regulatory developments affecting prothioconazole.
To map the value chain from raw materials such as 2-acetyl-γ-butyrolactone to prothioconazole end users, and to assess the degree of backward integration.
To profile the competitive environment, including the positioning of originator, integrated generic and contract manufacturers, and to track key developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study follows a structured, multi-stage research process. It begins with defining the market boundaries and segmentation, followed by extensive secondary research to build an understanding of the product, its synthesis routes, the downstream prothioconazole industry and the regulatory environment. Primary research with participants across the supply and demand sides is then used to validate assumptions, refine estimates and gather qualitative insights. Market size estimates are derived using both top-down and bottom-up approaches and are reconciled through data triangulation, after which forecasts for 2026–2032 are developed based on an analysis of demand drivers, capacity trends and regulatory outlook.
Secondary Research
Secondary research drew on a broad range of sources relevant to the agrochemical intermediates industry, including:
Government and regulatory bodies: pesticide registration databases and decisions published by the U.S. Environmental Protection Agency, the European Commission and the European Food Safety Authority, China's Institute for the Control of Agrochemicals, Ministry of Agriculture and Rural Affairs (ICAMA), India's Central Insecticides Board & Registration Committee, Brazil's Ministry of Agriculture and Livestock, and Health Canada's Pest Management Regulatory Agency.
Chemical regulators: substance registration and classification information from the European Chemicals Agency and national chemical inventories.
Company filings: annual reports, interim reports, stock exchange announcements, IPO prospectuses and environmental impact assessment disclosures of agrochemical producers and intermediate manufacturers.
Industry associations: publications of crop protection and chemical industry associations, including national pesticide industry associations in China and India.
Trade journals and patent literature: agrochemical trade publications, technical journals, and process patents covering the synthesis of the intermediate and prothioconazole.
Trade statistics and paid databases: customs and trade data, agrochemical market databases and company databases.
Primary Research
Primary research was conducted through in-depth interviews and structured discussions with industry participants to validate secondary findings and to obtain qualitative and quantitative inputs on pricing, capacity, purity requirements and demand trends.
Supply side: production and plant managers, business development and sales executives at intermediate manufacturers, integrated prothioconazole technical producers and contract manufacturers, as well as raw material suppliers.
Demand side: procurement and technical managers at prothioconazole technical producers and formulators, regulatory affairs specialists, and distributors and traders of agrochemical intermediates.
Objectives: to validate market size and segment splits, understand purity specifications and pricing dynamics, assess capacity utilisation and expansion plans, and gauge the outlook for downstream prothioconazole demand in each region.
Market Size Estimation
Top-down approach: The global prothioconazole technical market was used as the starting point. The requirement for 2-chloro-1-(1-chlorocyclopropyl)ethanone was derived from technical production volumes using process consumption ratios, and then converted to value using prevailing intermediate prices by purity grade. The resulting market was allocated to regions and countries based on downstream production and consumption patterns.
Bottom-up approach: Capacities, production and sales of individual manufacturers and integrated producers were estimated from company disclosures and primary interviews, aggregated by country and region, and adjusted for captive consumption, trade flows and inventory changes.
Data triangulation: Estimates from the top-down and bottom-up approaches were compared and reconciled. Differences were examined against primary interview inputs and secondary data points until a consistent market estimate was reached for each segment, region and country.
Forecasting Methodology
Forecasts for 2026–2032 were developed by modelling the expected growth of prothioconazole technical demand and production, and translating this into demand for the intermediate. The factors considered include:
Growth in cereal, soybean and oilseed rape acreage and fungicide application intensity in key agricultural regions.
New and pending registrations of prothioconazole and its mixtures across countries.
Announced and under-construction capacity for prothioconazole technical and its intermediates, and expected utilisation rates.
Price trends for technical and intermediate grades, reflecting competitive intensity and raw material costs.
Regulatory developments, including the European Union renewal process and maximum residue level changes.
Macroeconomic conditions, currency movements and trade policy.
Historic growth patterns, adjusted for these drivers, were used to establish growth trajectories for each segment, region and country, and the results were validated with industry participants.
Base Year, Forecast Period and Currency
Assumptions and Limitations
The intermediate is assumed to be used predominantly for prothioconazole synthesis throughout the forecast period, with no major alternative route displacing it commercially.
Average exchange rates for the base year were used to convert local-currency values to USD; future currency fluctuations are not factored into the forecast.
The study assumes that prothioconazole remains approved in its major markets during the forecast period, including the European Union following the current extension.
Captive production by integrated producers is valued at estimated market-equivalent prices, as such transfers are not separately disclosed.
Company-level production of the intermediate is rarely published; estimates therefore rely on capacity disclosures, environmental assessment documents and primary research.
Unforeseen events such as major plant shutdowns, trade restrictions or extreme weather affecting fungicide demand could cause actual outcomes to differ from the forecast.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone market is moderately fragmented. Its structure is closely tied to that of the prothioconazole technical industry, as most of the intermediate is produced captively by integrated technical manufacturers rather than traded on the open market. The originator, Bayer AG, operates its own integrated supply chain, while the post-patent generic segment is dominated by Chinese producers that have invested heavily in prothioconazole technical capacity and, increasingly, in dedicated intermediate units. A smaller merchant market exists in which specialised intermediate producers and traders supply technical manufacturers without captive capacity, research users and producers in regions without local production.
Competition is driven primarily by production cost, which depends on raw material integration, process yield and scale; by product quality, particularly purity and impurity profile; by environmental and safety compliance, which determines the ability to operate and expand; and by supply reliability. The rapid expansion of Chinese capacity has intensified price competition since 2021, and the market is expected to move towards consolidation around cost-efficient, integrated producers during the forecast period.
Key Player Positioning
Based on product portfolio, scale of capacity, degree of integration, regional reach and industry experience, the leading companies in the market can be grouped as leaders, challengers and niche players.
Leaders
Bayer AG (Germany): Founded in 1863 and headquartered in Leverkusen, Bayer discovered prothioconazole and launched it in 2004. It produces the technical captively and markets leading prothioconazole brands such as Proline, Aviator Xpro, Fox Xpro and Fox Supra. The group reported sales of EUR 45.6 billion in FY2025. Its strategy centres on defending the prothioconazole franchise through proprietary mixtures and leading the regulatory defence of the active ingredient.
Hailir Pesticides and Chemicals Group (China): Established in 1999 and headquartered in Qingdao, Hailir is an integrated producer of technicals and formulations and one of the first Chinese registrants of prothioconazole. It reported revenue of RMB 4,202.74 million in FY2025. The company has the most clearly disclosed in-house plan for this intermediate, with 9,461 tonnes per year of 2-chloro-1-(1-chlorocyclopropyl)ethanone included in its Qingdao Hengning project, alongside 10,000 tonnes per year of prothioconazole, and pursues backward integration into raw materials.
Anhui Jiuyi Agriculture Co., Ltd. (China): Founded in 2001 and based in Hefei, Jiuyi is among the largest suppliers of prothioconazole technical by volume, having commissioned a 5,000 tonnes per year plant. It reported revenue of RMB 1,493.44 million in FY2025. The company purchases its ketone intermediate from external suppliers, making it a significant buyer in the merchant market.
Challengers
ADAMA Ltd. (Israel): A global off-patent crop protection company and part of Syngenta Group, ADAMA began in-house production of prothioconazole in 2019 and opened a multi-purpose active ingredient plant in Taquari, Brazil, in 2023. It reported revenue of USD 4,051 million in FY2025 and focuses on differentiated prothioconazole mixtures for Brazilian soybean and European cereals.
CAC Nantong Chemical (Taihe) (China): Based in Nantong, Jiangsu, and listed on the Shenzhen ChiNext board in April 2025, Taihe reported revenue of RMB 5.37 billion in FY2025. It produces prothioconazole technical through its subsidiary Jiangxi Tianyu and has completed a self-built prothioconazole and trifloxystrobin technical-and-intermediate project, with a further intermediate project funded from listing proceeds.
ABA Chemicals (China): Founded in 2006 and headquartered in Taicang, Jiangsu, ABA is a contract development and manufacturing company for agrochemical and pharmaceutical intermediates. It reported revenue of RMB 1.31 billion in FY2025 and is expanding prothioconazole technical capacity at its Nantong subsidiary, leveraging relationships with multinational agrochemical customers.
Yifan Biotechnology Group (China): Yifan operates a 1,500 tonnes per year prothioconazole technical plant in Ningxia, which started production in 2023, and markets prothioconazole mixtures through its subsidiary Jiangsu Yunfan Chemical. Revenue is not publicly disclosed.
Hebei Xingbai (China): A private agrochemical producer that began constructing a 10,000 tonnes per year prothioconazole project in 2023, to be built in phases. Revenue is not publicly disclosed.
Niche Players
Jiangsu Changqing Agrochemical (China): A pesticide technical and formulation producer with revenue of RMB 3,685.64 million in FY2025. The company is building a 1,000 tonnes per year prothioconazole technical project at its Hubei base, funded by redirected listing proceeds, as part of a shift towards fungicides.
Hikal Ltd. (India): A contract manufacturer and producer for pharmaceutical and crop protection innovators, headquartered in Mumbai, with revenue of INR 1,860 crore in FY2025 (year ended March 2025). Hikal lists prothioconazole technical among its crop protection products and has filed a patent application for an industrial-scale prothioconazole process.
Competitor Dashboard
The competitor dashboard below rates each profiled company on four parameters: breadth of product portfolio relevant to the prothioconazole value chain, regional presence, strategic alliances and industry experience.
Threat of New Entrants: Medium
The synthesis route is well documented in patents and literature following patent expiry, lowering technological barriers.
Entry requires substantial capital investment, environmental impact approval and siting within approved chemical parks, which limits new capacity.
Established integrated producers benefit from scale, raw material access and existing customer relationships.
Bargaining Power of Suppliers: Medium
Chlor-alkali inputs such as chlorine and sodium hydroxide are widely available commodities.
Supply of 2-acetyl-γ-butyrolactone is more concentrated, giving its producers some pricing influence during periods of tight supply.
Backward integration by leading producers reduces dependence on external suppliers.
Bargaining Power of Buyers: High
Buyers are prothioconazole technical producers that are price-sensitive owing to overcapacity in the technical market.
Many large buyers can produce the intermediate captively, strengthening their negotiating position with merchant suppliers.
Buyers require stringent quality documentation, giving them leverage when selecting and switching suppliers.
Threat of Substitutes: Low
There is no commercially established alternative intermediate for the industrial synthesis of prothioconazole at scale.
Substitution risk exists mainly at the fungicide level, where other triazoles, SDHIs and strobilurins compete with prothioconazole.
Alternative patented routes are emerging but have not yet displaced the established ketone route.
Intensity of Competitive Rivalry: High
Numerous Chinese producers have built or announced capacity, intensifying price competition.
Products are largely undifferentiated beyond purity and impurity profile, making price a key purchasing criterion.
Declining technical prices transmit directly to the intermediate, increasing rivalry for available demand.
Threat of New Entrants: Medium; Known technology offset by capital, environmental and siting barriers.
Bargaining Power of Suppliers: Medium; Commodity chlor-alkali inputs; more concentrated supply of 2-acetyl-γ-butyrolactone.
Bargaining Power of Buyers: High; Price-sensitive technical producers with captive production options.
Threat of Substitutes: Low; No established alternative intermediate at commercial scale.
Competitive Rivalry: High; Rapid Chinese capacity growth and falling prices.
Market estimates by geography (2032)
InsightAsia Pacific leads with $21.94M by 2032, while Middle East & Africa is projected to grow fastest at a 9.0% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $0.96M | $1.20M | $1.54M | 4.8% | 5% |
| Europe | $1.29M | $1.59M | $1.99M | 4.4% | 7% |
| Asia Pacific | $11.60M | $16.04M | $21.94M | 6.6% | 78% |
| Latin America | $0.85M | $1.27M | $1.85M | 8.0% | 7% |
| Middle East & Africa | $0.28M | $0.43M | $0.66M | 9.0% | 2% |
| Total | $14.98M | $20.53M | $27.96M | 6.4% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$27.96M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Prothioconazole | $24.27M | 6.8% | 87% |
| Others | $3.69M | 4.4% | 13% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market covering market dynamics, competitive landscape, and strategic outlook.
The 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market market is projected to reach $27.96M by 2032, growing at 6.4% CAGR. The Prothioconazole segment holds the largest share.
The global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone market is driven primarily by the production economics and end-use demand of prothioconazole, which accounts for 85.0% of market value in 2025. The market dynamics therefore reflect the interplay between agricultural demand for fungicides, the post-patent expansion of generic prothioconazole technical manufacturing, the regulatory environment for both the active ingredient and chemical manufacturing, and the competitive behaviour of integrated producers. This chapter evaluates these forces through a growth factor analysis and a discussion of drivers, restraints, opportunities, and key trends and challenges.
The growth factor analysis below assesses five macro-level and five micro-level factors. Each factor is classified by impact type as promoting, inhibiting or steady, and is assigned an impact score out of 10 for three time windows within the forecast period. The scores are analyst assessments based on secondary research and industry interviews, where a higher score indicates a stronger influence on market development in that period.
Expansion of Generic Prothioconazole Production Following Patent Expiry
The core compound patents for prothioconazole expired in 2015, followed by the U.S. process patent in 2018 and Bayer's Chinese crystal-form patent in July 2023. These expiries opened the active ingredient to generic manufacturers and triggered a wave of technical registrations and capacity investments. In China, prothioconazole was first registered in January 2019, and the country recorded ten technical registrations for prothioconazole in 2023, the highest number for any active ingredient that year. In the United States, the Environmental Protection Agency approved a generic prothioconazole technical from Life Scientific in December 2022, and more than 40 prothioconazole products had been registered in the U.S. by early 2024. Each new technical producer requires a reliable supply of 2-chloro-1-(1-chlorocyclopropyl)ethanone, either through captive production or merchant purchase, so the broadening producer base directly increases the number of buyers and the volume requirement for the intermediate. This structural shift underpins the growth of the Prothioconazole segment from USD 15.396 Million in 2025 to USD 24.271 Million in 2032.
Rising Fungicide Demand in Cereal and Soybean Cultivation
Prothioconazole is one of the most widely used fungicides for cereals and is a key tool against diseases such as Fusarium head blight, septoria and rusts in wheat and barley, as well as Asian soybean rust and other foliar diseases in soybean. Demand is reinforced by the need to manage resistance through mixtures and to protect yields as fungal disease pressure varies with changing weather patterns. In Brazil, the most important single market for prothioconazole, new mixtures continue to be introduced: Bayer presented Fox Supra, a combination of prothioconazole and impirfluxam for soybean, in February 2023, and ADAMA opened a multi-purpose active ingredient plant at Taquari in Brazil in the same month to supply its prothioconazole-based products. In China, the rapid increase in prothioconazole product registrations, which reached 64 products including 32 technical registrations by May 2024, reflects strong uptake in wheat disease control. This expanding end-use base sustains demand for the intermediate across regions, particularly in Latin America, which is projected to grow at a CAGR of 7.82%.
Backward Integration and Investment in Intermediate Capacity
As prothioconazole technical prices have fallen, producers have sought to control costs and secure supply by integrating backward into the key intermediates. Hailir Pesticides and Chemicals Group revised its Qingdao Hengning project in April 2023 to include 9,461 tonnes per year of 2-chloro-1-(1-chlorocyclopropyl)ethanone alongside 10,000 tonnes per year of prothioconazole, with total project investment raised to RMB 2,021.31 million. CAC Nantong Chemical (Taihe) completed a self-built prothioconazole and trifloxystrobin technical-and-intermediate project and has committed additional listing proceeds to a dedicated intermediate project. Several other Chinese producers have announced intermediate units linked to technical plants. Such investments create dedicated demand for the intermediate, raise the technical standards of its manufacture, and support the steady growth of production volumes over the forecast period.
Regulatory Equivalence Requirements Supporting High-Purity Grades
Generic prothioconazole technicals must demonstrate equivalence to the reference specification, including limits on relevant impurities, to gain registration in the European Union, the United States and many other jurisdictions. Achieving a consistent impurity profile in the final technical depends heavily on the quality of the cyclopropyl ketone intermediate, as by-products formed during chlorination and cyclisation can carry through to the active ingredient. Producers seeking access to regulated export markets, such as Hailir, which has obtained EU equivalence for its prothioconazole technical, therefore favour intermediate grades of 98% purity and above. This requirement explains why the 98% & Above segment accounted for 80.0% of the market in 2025 and is projected to grow at a CAGR of 6.95%, faster than the overall market.
Upstream Integration into Key Raw Materials
Integration from 2-acetyl-γ-butyrolactone through the chlorinated pentanone and cyclopropyl ketone stages to prothioconazole technical offers a sustainable cost advantage in a market characterised by price competition. Producers such as Hailir have taken equity stakes in upstream raw material suppliers, and Chinese chemical companies have announced new 2-acetyl-γ-butyrolactone capacity aimed at prothioconazole supply chains. Companies able to combine raw material security with efficient intermediate production are well placed to supply both their own technical units and third-party buyers.
Supply to Emerging Generic Registrants and Growing Agricultural Markets
As prothioconazole registrations broaden across Latin America, India, Southeast Asia and the Middle East & Africa, new formulators and technical producers are emerging that may not have captive intermediate production. This creates opportunities for merchant suppliers offering consistent, high-purity material with full documentation. The Middle East & Africa (CAGR 8.84%) and Latin America (CAGR 7.82%) are the fastest-growing regions in this market, while India, growing at 8.26%, is the fastest-growing major producing country, supported by domestic process patents for prothioconazole held by companies such as UPL, GSP Crop Science and Hikal.
Process Innovation and Greener Manufacturing Routes
Improvements in reaction selectivity, solvent recovery and waste minimisation offer meaningful opportunities to reduce cost and environmental burden. Patent activity continues in this area, including one-pot chlorination and cyclisation routes and alternative pathways to prothioconazole intermediates, such as the route patented by Jiangsu Sevencontinent Green Chemical in 2024. The adoption of continuous-flow chlorination, phase-transfer catalysis optimisation and improved by-product recovery can enable producers to achieve higher purity at lower cost, supporting access to regulated markets and strengthening competitiveness.
Overcapacity and Price Erosion in the Prothioconazole Value Chain
Built, under-construction and planned prothioconazole technical capacity in China has grown far faster than global consumption, and industry reviews have repeatedly warned of severe overcapacity. Technical prices have fallen sharply since 2021, compressing margins for producers and placing continuous pressure on intermediate prices. Disclosures by Chinese producers show declining gross margins on prothioconazole technical between 2023 and 2025. Because the intermediate is valued largely on a cost-plus basis relative to technical prices, this price erosion restrains value growth even where volumes increase, and it may lead to delays or cancellations of announced intermediate projects.
Environmental and Process Safety Constraints
The synthesis of 2-chloro-1-(1-chlorocyclopropyl)ethanone involves chlorination with chlorine or sulfuryl chloride, strongly basic cyclisation and the handling of chlorinated organic by-products, generating acidic off-gases and saline, organically loaded wastewater. Plants must meet stringent requirements for environmental impact assessment, process safety review and hazardous chemical management, particularly in China, where chemical production has been concentrated into approved chemical parks and subjected to tighter inspection regimes. These requirements raise capital and operating costs, lengthen project timelines and can restrict the entry of new producers.
Regulatory Uncertainty for Prothioconazole in Key Markets
The renewal of prothioconazole under Regulation (EC) No 1107/2009 has been under review in the European Union since 2018, including an assessment of endocrine-disrupting properties. Commission Implementing Regulation (EU) 2025/787 extended the approval period to 31 March 2027. While the draft renewal assessment report released in 2023 indicated that prothioconazole does not meet the endocrine disruptor criteria, the final outcome and any restrictions on use or residue limits remain a source of uncertainty for demand in Europe, which is the slowest-growing region in this market.
Consolidation and Rationalisation of Chinese Capacity
Following a phase of rapid capacity announcements, the Chinese prothioconazole industry is entering a period of rationalisation. Some planned projects have been delayed, scaled back or redirected, and listing plans of certain producers have been withdrawn or terminated. Over the forecast period, capacity is expected to concentrate among integrated, cost-efficient producers with strong environmental compliance, which will shape purchasing patterns for the intermediate.
Growth of Prothioconazole-Based Mixtures
Formulators are increasingly combining prothioconazole with partners such as trifloxystrobin, tebuconazole, bixafen, fluopyram, impirfluxam and picoxystrobin to broaden disease spectrum and manage resistance. China approved its first prothioconazole and picoxystrobin water-dispersible granule registration in July 2025, and ADAMA registered prothioconazole-based cereal fungicides in several European countries in 2025. The growth of mixtures extends the commercial life of prothioconazole and supports demand for its intermediates.
Supply Chain Diversification Towards India
Global crop protection companies are seeking to diversify sourcing of active ingredients and intermediates beyond a single country. India, with an established agrochemical manufacturing base and growing process capabilities for prothioconazole, is a beneficiary of this trend. However, Indian producers face cost competition from large-scale Chinese plants and must build scale in upstream raw materials to compete effectively.
Margin Pressure and Working Capital Challenges
Volatile technical prices, high inventory levels in the distribution chain and extended payment terms in key agricultural markets create working capital challenges for producers throughout the value chain. Intermediate suppliers face the risk of order fluctuations as technical producers adjust utilisation rates, underscoring the importance of long-term supply agreements and flexible multi-purpose production assets.
The value chain for the 2-Chloro-1-(1-Chlorocyclopropyl)ethanone market extends from basic chemical inputs to the farmers who apply prothioconazole-based fungicides. A high degree of vertical integration is a defining characteristic, as many prothioconazole technical producers manufacture the intermediate captively.
Raw Materials and Inputs
The principal inputs are 2-acetyl-γ-butyrolactone or chlorinated pentanones (such as 5-chloro-2-pentanone), chlorinating agents including chlorine and sulfuryl chloride, sodium hydroxide, phase-transfer catalysts and solvents. Availability of 2-acetyl-γ-butyrolactone and the cost of chlor-alkali products are the main determinants of raw material cost.
Manufacturing
Manufacturing involves chlorination and ring-opening steps to form chlorinated pentanones, base-mediated cyclisation to 1-acetyl-1-chlorocyclopropane, and α-chlorination to the target ketone, followed by purification by distillation to the required grade. Producers include integrated prothioconazole technical manufacturers operating captive units, specialised intermediate producers and contract manufacturers.
Distribution and Channels
The bulk of volume moves through captive transfer within integrated groups or through direct long-term supply contracts between intermediate producers and technical manufacturers. Smaller volumes are sold through chemical traders and distributors, particularly for research, development and pilot-scale use, and for export to producers in regions without local intermediate capacity.
End Users
The direct end users are prothioconazole technical producers and, to a lesser extent, manufacturers of other agrochemical and fine-chemical products. Their output is formulated into fungicide products sold to farmers growing cereals, soybean, oilseed rape, pulses and other crops, so final demand is governed by agricultural conditions and crop protection practices.
The market is influenced by two layers of regulation: rules governing the manufacture, handling and trade of the chemical intermediate, and rules governing the registration and use of prothioconazole as a plant protection product.
North America
United States: Prothioconazole is registered under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), with residue tolerances established under the Federal Food, Drug, and Cosmetic Act. The EPA issued an interim registration review decision for prothioconazole in 2021. Chemical intermediates imported or manufactured for commercial purposes may also be subject to the Toxic Substances Control Act (TSCA).
Canada: Pest control products are regulated under the Pest Control Products Act, administered by Health Canada's Pest Management Regulatory Agency, while industrial chemicals fall under the Canadian Environmental Protection Act, 1999.
Europe
European Union: Active substances are approved under Regulation (EC) No 1107/2009; the approval of prothioconazole was extended to 31 March 2027 by Commission Implementing Regulation (EU) 2025/787. Maximum residue levels are set under Regulation (EC) No 396/2005. The intermediate is subject to REACH (Regulation (EC) No 1907/2006) and to classification and labelling under the CLP Regulation (EC) No 1272/2008.
United Kingdom: Plant protection products are regulated under the Great Britain regime administered by the Health and Safety Executive, and chemicals are subject to UK REACH.
Asia Pacific
China: Pesticide registration and production are governed by the Regulations on Pesticide Administration, with registration administered by ICAMA under the Ministry of Agriculture and Rural Affairs. Manufacturing is subject to the Regulations on the Safe Management of Hazardous Chemicals and environmental impact assessment requirements.
India: Pesticides are regulated under the Insecticides Act, 1968 and the Insecticides Rules, 1971, administered by the Central Insecticides Board & Registration Committee. Manufacture of hazardous chemicals is governed by the Manufacture, Storage and Import of Hazardous Chemical Rules, 1989 under the Environment (Protection) Act, 1986.
Japan: Pesticides are regulated under the Agricultural Chemicals Regulation Act, and industrial chemicals under the Chemical Substances Control Law.
Latin America
Brazil: Pesticide registration is governed by Law No. 14,785 of 2023, which replaced the previous pesticide law, with the Ministry of Agriculture and Livestock as the lead registration authority alongside health and environmental agencies.
Argentina: Plant protection products are registered by the National Agri-Food Health and Quality Service (SENASA).
Middle East & Africa
South Africa: Agricultural remedies are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).
Gulf countries: Pesticide registration is administered by national authorities, such as the Ministry of Environment, Water and Agriculture in Saudi Arabia and the Ministry of Climate Change and Environment in the UAE.
The table below summarises key developments by market participants from 2022 onward, including capacity expansions, product launches, registrations and investments.
Jun 2022: Anhui Jiuyi Agriculture; Expansion; Filed for a ChiNext listing to fund a 5,000 tonnes per year prothioconazole technical project.
Dec 2022: Hailir Pesticides and Chemicals Group; Expansion; The 3,000 tonnes per year prothioconazole technical project at Shandong Hailir entered trial production.
Dec 2022: Life Scientific; Registration; The U.S. EPA approved LS Prothioconazole Technical, a generic prothioconazole technical.
Feb 2023: ADAMA Ltd.; Expansion; Opened a multi-purpose active ingredient plant at Taquari, Brazil, with investment of over USD 50 million, producing prothioconazole for its global pipeline.
Feb 2023: Bayer AG; Product Launch; Presented Fox Supra, a prothioconazole and impirfluxam fungicide for soybean, at Show Rural Coopavel in Brazil.
Feb 2023: Hebei Xingbai; Expansion; Started construction of a 10,000 tonnes per year prothioconazole project, planned in phases of 3,000 and 7,000 tonnes.
Apr 2023: Hailir Pesticides and Chemicals Group; Expansion; Revised the Qingdao Hengning project to 10,000 tonnes per year of prothioconazole and 9,461 tonnes per year of 2-chloro-1-(1-chlorocyclopropyl)ethanone, with total investment of RMB 2,021.31 million.
Apr 2023: ABA Chemicals; Expansion; Its prothioconazole technical plant passed process safety review.
Jun 2023: Yifan Biotechnology Group; Expansion; Ningxia Yifan started production at its 1,500 tonnes per year prothioconazole technical plant.
2024: Anhui Jiuyi Agriculture; Expansion; Started up the first three production lines of its 5,000 tonnes per year prothioconazole technical plant.
Feb 2025: ABA Chemicals; Expansion; Received environmental impact assessment approval for a project including 2,000 tonnes per year of prothioconazole technical at Nantong.
Apr 2025: CAC Nantong Chemical (Taihe); Investment; Listed on the ChiNext board, with proceeds allocated to prothioconazole and trifloxystrobin technical and intermediate projects.
Apr 2025: Hailir Pesticides and Chemicals Group; Investment; Approved an additional RMB 781.87 million investment at Qingdao Hengning, retaining the 9,461 tonnes per year intermediate scope.
Jul 2025: Yifan Biotechnology Group; Registration; Subsidiary Jiangsu Yunfan Chemical received China's first registration for a prothioconazole and picoxystrobin water-dispersible granule.
Sep 2025: Jiangsu Changqing Agrochemical; Investment; Shareholders approved redirecting listing proceeds to a 1,000 tonnes per year prothioconazole technical project in Hubei.
Q4 2025: ADAMA Ltd.; Registration; Registered the prothioconazole-based cereal fungicides AVASTEL in Hungary, Austria and the Netherlands, and SORATEL in Estonia.
Aug 2026: CAC Nantong Chemical (Taihe); Expansion; Reported completion of its self-built prothioconazole and trifloxystrobin technical-and-intermediate project, with RMB 333.54 million committed to a separate intermediate project.
Political
Government emphasis on food security in China, India and Brazil supports fungicide use and domestic agrochemical manufacturing.
Trade tensions and tariffs between major economies influence sourcing decisions for agrochemical intermediates and encourage supply diversification.
Industrial policies that relocate chemical production into designated parks shape where new capacity can be built.
Economic
Farm incomes and crop prices drive fungicide spending and, in turn, demand for prothioconazole and its intermediates.
Overcapacity in Chinese prothioconazole technical has led to sharp price declines and margin pressure across the value chain.
Currency movements, particularly of the Chinese yuan, Indian rupee and Brazilian real, affect export competitiveness and import costs.
Social
Rising population and changing diets increase demand for cereals and oilseeds, supporting crop protection use.
Growing public concern over pesticide residues influences regulatory scrutiny and residue limits.
Technological
Process improvements in cyclisation and chlorination steps raise yields and purity, lowering production cost.
Continuous-flow and phase-transfer technologies improve safety and reduce waste in chlorination chemistry.
Alternative patented routes to prothioconazole intermediates may change raw material requirements over time.
Environmental
Chlorination processes generate acidic off-gases and saline wastewater, requiring investment in treatment and recovery.
Climate variability affects fungal disease incidence and therefore fungicide demand from season to season.
Stricter emission and discharge standards increase compliance costs for producers.
Legal
Registration requirements for technical equivalence set impurity limits that influence intermediate specifications.
The EU renewal process for prothioconazole and changes to maximum residue levels affect demand in Europe and in export markets supplying the EU.
Process patents held by originators and generic producers shape the freedom to operate for specific synthesis routes.
Profiles of 31 companies operating in the 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market market, including revenue, employee count, and market positioning where available.
Showing 31 of 31 companies
ADAMA is the world's leading pure-play off-patent crop protection company and the "value" arm of Syngenta Group. It does not discover new chemistry at the scale of the research majors; instead it takes active ingredients that have lost or are about to lose patent protection and re-engineers them through proprietary formulation platforms (Asorbital, Sesgama, T.O.V., Desidro, Ayalon) into mixtures that offer growers a measurable agronomic benefit at a lower price point than originator brands. It sells roughly USD 4 billion a year of herbicides, insecticides and fungicides, with a balanced footprint across Europe, North America, Latin America and Asia-Pacific, backed by back-integrated synthesis in Israel, China and Brazil. After a severe 2023–2024 downturn caused by channel destocking and Chinese active-ingredient overcapacity, the "Fight Forward" programme has restored margins and cash generation, although statutory earnings only turned positive in the first half of 2026 and leverage remains elevated. --- **What the company says.** In its results releases ADAMA describes itself as a global crop protection leader that supplies practical solutions to farmers for weeds, insects and disease, built on a diverse portfolio of existing active ingredients, formulation capability and proprietary formulation technology platforms. It states that it serves customers in dozens of countries with a direct presence in all of the top 20 agricultural markets (FY2025 PR, "About ADAMA"). Earlier boilerplate (FY2022 PR) referred to sales in more than 100 countries; the narrower current wording is consistent with the Fight Forward decision to concentrate on priority countries. **Independent characterisation.** ADAMA is an integrated post-patent agrochemical manufacturer and marketer. Its economics rest on four activities: 1. **Registration and regulatory work.** Value in off-patent crop protection is gated by product registrations country by country. ADAMA obtained 174 new registrations in 2025 and maintains a registration network covering more than 80 countries (2025 Annual Report, as summarised by Sohu Finance and Dongxing Securities). 2. **Formulation and mixture design.** The company manages more than 300 active ingredients centrally and about 1,300 end-use mixtures and formulations (Dongxing Securities note of 7 April 2026, citing the 2025 Annual Report). "Differentiated" products accounted for 45% of crop protection sales excluding active-ingredient sales in 2025. 3. **Manufacturing.** Synthesis of selected active ingredients and formulation at sites principally in Israel, China and Brazil (FY2025 PR). The company has moved away from producing certain basic chemicals in China and is explicitly shifting to a more flexible, asset-light supply network (H1 2026 PR). 4. **Go-to-market.** Sales are made mainly to distributors, retailers and cooperatives, with farmer-facing demand generation in priority markets. A smaller Consumer & Professional Solutions business in North America sells home, garden and professional pest-control products. **Revenue model.** Revenue is almost entirely product sales. There is no material subscription, licensing or service revenue disclosed; the December 2025 BASF agreement on Gilboa introduces a co-development and commercialisation arrangement whose financial terms are not publicly disclosed. In FY2025, Crop Protection contributed USD 3,730 million (92%) and Intermediates & Ingredients USD 321 million (8%) (FY2025 PR). **Value chain position.** ADAMA sits between upstream chemical intermediates suppliers (largely Chinese) and agricultural distribution. It is partially back-integrated into chlor-alkali and key intermediates, and buys a significant share of technical-grade active ingredients externally. This makes gross margin sensitive to the timing gap between falling procurement costs and falling selling prices, visible in the margin compression of 2023 and the recovery of 2024–2025. **Customers and end-markets.** End-users are growers of row crops (soybean, corn, cereals, cotton, rice, sugarcane), fruit and vegetables, and speciality crops. Non-agricultural customers include consumer and professional pest-control channels in North America and industrial buyers of intermediates, aroma chemicals and other non-ag products.
Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
Nippon Soda is a mid-cap, diversified Japanese chemical group founded in 1920 as a chlor-alkali producer and progressively re-shaped into a portfolio anchored by two high-value franchises: research-based crop protection (Agri Business, 35% of FY3/26 sales) and specialty "Chemical Materials" (25%), complemented by lower-margin but stable trading/logistics, plant engineering and environmental-recycling businesses. Its crown jewels are niche, high-barrier products in which it holds globally relevant positions — the pharmaceutical excipient NISSO HPC (hydroxypropyl cellulose), liquid polybutadiene NISSO-PB for AI-server copper-clad laminates, KrF photoresist polymer VP-POLYMER, and proprietary agrochemicals such as Mospilan (acetamiprid) and Topsin-M. With FY3/26 net sales of JPY 152.1 billion, record net profit of JPY 18.3 billion, an equity ratio of ~66.6%, and a 50%+ total shareholder return policy, the company is a conservatively financed, R&D-led specialty player now pivoting toward healthcare (including animal health) and advanced ICT materials under its Stage III plan to FY3/30. --- ### Company's own description According to its Stage III medium-term plan (May 2026), Nippon Soda describes its mission as creating new value through the power of chemistry, and frames the group as supporting everyday life through chemical products and services across four "material" fields: Agriculture (securing food and sustainable agriculture), Healthcare (healthy life for all people), Environment (toward a resource-recycling society) and ICT (chemical functions for IT devices). The Yuho describes the parent's business as manufacturing, processing and marketing of industrial chemicals, synthetic resins and plastics, dyes, pharmaceuticals, agrochemicals, veterinary pharmaceuticals and other chemical products. ### Business model and revenue model Nippon Soda's revenue is overwhelmingly product-based (manufactured chemical sales), with secondary service revenues from logistics (warehousing, transport, customs brokerage), engineering/EPC contracts and waste treatment. There is no material subscription revenue. Licensing/active-ingredient supply is embedded in Agri Business: the company supplies proprietary active ingredients (AIs) to global majors and sells formulated products through its own overseas network and partners. The revenue mix by nature (approximation from FY3/26 segment data; company does not disclose a product/service split): *Note: the above split is an analytical characterization; the company does not report revenue by nature.* ### Value-chain position **Agri Business:** fully integrated R&D-type agrochemical originator — chemical synthesis, biological/safety research, formulation research, field evaluation, AI manufacturing (including via Nisso Namhae Agro in Korea) and formulation, registration and global marketing (Stage III plan). The company emphasizes that R&D-type agrochemical originators are largely limited to five overseas majors plus Japanese firms, and that Japanese originators punch above their weight in new AI discovery. **Chemical Materials:** upstream chlor-alkali (caustic soda, chlorine, hydrochloric acid) feeding downstream fine/specialty chemistry (living anionic polymerization for NISSO-PB and VP-POLYMER; cellulose derivatization for HPC; penem API synthesis). **Trading & Logistics:** captive and third-party distribution (Nisso Shoji) and specialized hazardous/pharma logistics (Sanwa Soko, Sanso Unyu). **Engineering:** fine-chemical-type EPC (Nisso Engineering) and civil works (Nisso Kensetsu). **Eco Solutions:** waste treatment, zinc recovery from electric-arc-furnace dust, sulfuric acid recycling (Nisso Metallochemical). ### Customer types and end-markets Customers include global agrochemical majors and distributors, farmers' cooperatives (via channels), generic and innovator pharmaceutical companies and supplement makers (HPC, SSF, faropenem API), copper-clad-laminate (CCL) and semiconductor-materials producers (NISSO-PB, 1,2-SBS, VP-POLYMER), thermal-paper manufacturers (color developers), battery-materials producers, industrial users of commodity chemicals, steelmakers (EAF dust treatment), and public/private construction clients (Engineering). End-markets: crop protection (fruit & vegetables first, expanding to grains), pharmaceuticals/nutraceuticals, semiconductors/electronics (AI servers, HBM, automotive chips), infrastructure, and environmental services. ### Independent characterization Nippon Soda is best understood as two engines and three stabilizers. The engines — Agri Business and specialty Chemical Materials — generated roughly 75% of FY3/26 segment operating profit (JPY 11.2 billion of JPY 14.97 billion before adjustments) on 60% of sales. Agri is cyclical and FX-sensitive (65.7% overseas sales ratio in FY3/26), while Chemical Materials has been structurally re-rated from a ~5–6% margin business to ~15–17% after exiting commodity lines (metallic sodium via Alkaline S.A.S., NISSO HI-CHLON, phenol-based color developers, sodium cyanide). The stabilizers (Trading & Logistics, Engineering, Eco Solutions) are low-growth and modest-margin but add scale and cash. A further, often-overlooked profit pillar is equity-method income (JPY 6.06 billion in FY3/26, chiefly Iharabras in Brazil), which made ordinary profit (JPY 22.99 billion) much larger than operating profit and is highly FX-sensitive (BRL/USD).
RPM International is a holding company for more than a dozen semi-autonomous specialty-chemicals franchises. These businesses make coatings, sealants, roofing, concrete admixtures, flooring, fireproofing and building-envelope systems, mostly for maintenance, repair and restoration rather than new construction. Its brand portfolio is unusually deep for a USD 7.9 billion company: Rust-Oleum, DAP, Zinsser, Varathane and The Pink Stuff on the consumer side; Tremco, Euclid, Dryvit, Nudura, Kalzip, Stonhard, Carboline and Fibergrate on the professional side. Each brand holds a leading position in a niche that larger diversified coatings groups do not dominate. Since 2018 RPM has run successive operational-improvement programs (MAP to Growth, MAP 2025, and now "MAP 3.0"). These have lifted gross margin from about 36% (FY2022) to about 41% (FY2026) and moved the group from a loose federation toward a centrally coordinated operating company. RPM is a disciplined, dividend-growing compounder with 52 consecutive annual dividend increases. Its growth vectors are engineered building systems, emerging markets (the "Platform" model) and bolt-on M&A. --- ### Company's own description (FY2026 Form 10-K, Item 1) RPM describes itself as follows: its subsidiaries manufacture, market and sell specialty chemical product lines, including high-quality specialty paints, infrastructure rehab and repair products, protective coatings, roofing systems, sealants and adhesives. These products focus on the maintenance and improvement needs of the construction, industrial, specialty and consumer markets. Footprint as of 31 May 2026: - Products marketed in about 167 countries and territories. - Manufacturing in about 120 locations across 22 countries. - About 31% of sales generated internationally: foreign operations 29.8% of net sales, plus direct U.S. exports of 0.9%. The press-release boilerplate calls RPM "a world leader in specialty coatings, sealants, building materials and related services." ### Business model RPM's model has four defining features. - **Decentralised entrepreneurial structure, becoming more integrated.** The founder's philosophy, still quoted in the 2026 proxy, is: "Hire the best people you can find. Create an atmosphere that will keep them. Then let them do their jobs." Operating companies historically kept their own brands, sales forces and ERP systems. The MAP programs are deliberately centralising procurement, manufacturing, accounting and IT. The stated goal is to consolidate more than 75 ERP systems to one platform per segment (Q4 FY2026 8-K). **Repair and maintenance bias:** Much of the portfolio serves existing assets: roof restoration, re-cover, concrete repair, corrosion control, rust prevention and DIY touch-up. That demand is less cyclical than new-build construction. The FY2026 10-K notes that re-roofing has historically accounted for over three-quarters of U.S. roofing demand. **Systems and turnkey selling:** In CPG and PCG, RPM increasingly sells integrated systems (the "Power of One" building envelope) and supply-and-apply turnkey services. Examples include Stonhard flooring installation and Weatherproofing Technologies roofing services. This captures more of each construction project's spend. **Bolt-on M&A plus organic growth:** RPM completed six acquisitions in each of FY2025 and FY2026 (FY2026 10-K Note F). ### Revenue model mix | Revenue type | Characterisation | Evidence | |---|---|---| | Product sales | Dominant (estimated well above 90% of revenue; exact split not publicly disclosed) | Manufactured coatings, sealants, admixtures and similar products sold through retail, distribution and direct channels | | Installation and services | Material within CPG and PCG; not separately disclosed | WTI/WTC roofing services, turnkey general contracting, TremCare maintenance programs, Stonhard installed flooring, Legend Brands/RoofTec restoration services, Pure Air Control Services | | Warranty and extended programs | Embedded in pricing; generates deferred revenue | Current unearned revenue USD 75.3M and long-term unearned revenue USD 92.4M at FY2026 (standardized balance sheet) | | Licensing and royalties | Minor | The 10-K notes license fees and royalty income from numerous international license agreements, plus equity-method joint ventures | | Subscription | None identified | — | RPM does not disclose a product versus service versus licensing split. From filings, the mix is: ### Value-chain position RPM is a formulator and brand owner, positioned downstream of commodity chemical producers. It buys petroleum-derived resins, solvents, pigments, minerals, metals and packaging (FY2026 10-K, Raw Materials). It is selectively backward-integrated: RPM cites expanding in-house raw material production, and Arnette Polymers makes amine curing agents and epoxy intermediates. Channels downstream include: - Mass merchants and home centres, where the single largest Consumer customer was 20% of Consumer sales in FY2026. - Hardware and paint stores. - Distributors. - Contractors and specifiers. - Direct sales to industrial plant owners, public institutions and infrastructure agencies. ### Customer types and end markets | End market | Segment exposure | Representative brands | |---|---|---| | Commercial / institutional building envelope (roofing, walls, waterproofing, sealants) | CPG | Tremco, Dryvit, Nudura, illbruck, Kalzip, Volteco | | Concrete, cement and infrastructure | CPG, PCG | Euclid, Toxement, Viapol, Prime Resins, Fibrecrete | | Industrial maintenance, oil and gas, petrochemical, power, data centres | PCG | Carboline, Stonhard, Fibergrate, Nullifire | | Food and pharma | PCG | Mantrose-Haeuser, NatureSeal, Profile Food Ingredients | | Marine, wood finishes, powder coatings | PCG | Pettit, Woolsey, FinishWorks/Mohawk, TCI | | Residential DIY and professional painters | Consumer | Rust-Oleum, Zinsser, Varathane, DAP | | Household cleaning | Consumer | The Pink Stuff, Krud Kutter, Mean Green | | Pigments, colorants, OEM and personal care | Consumer (Color Group) | Day-Glo | | Restoration services equipment | CPG (Legend Brands) | Dri-Eaz, Sapphire Scientific | ### Independent characterisation RPM is best understood as a portfolio of niche category leaders with a structural margin-improvement story layered on top. The professional segments (CPG and PCG) are about 66% of sales and supply the growth. In FY2026 they posted record results driven by high-performance buildings, data centres, infrastructure, fireproofing and concrete admixtures. In Q1 FY2027, emerging-market regions grew more than 20%. The Consumer segment is about 34% of sales. It is a cash-generative but volume-challenged DIY business. Organic Consumer sales fell 0.8% in Q4 FY2026 and 4.7% in Q2 FY2026. They recovered to +5.2% in Q1 FY2027 on shelf-space wins and pricing. The equity debate therefore centres on three questions: 1. Can MAP savings and pricing protect margins against renewed raw-material inflation linked to the Middle East conflict? 2. Is the Q1 FY2027 CPG slowdown temporary? 3. Will the 9 November 2026 investor day credibly frame the next margin plan?
Company Headquarters: Amsterdam, Netherlands Founded: 1994 Workforce: ~35,200 Company Working: Akzo Nobel N.V. operates its business by manufacturing products of various industries such as decorative paints, automotive & specialty coatings, industrial coatings, powder coating and marine, protective and yacht coatings. The automotive and specialty coatings segment of the business comprises products such as aerospace coatings, consumer electronics coatings, automotive OEM coatings, vehicle refinishes and sign finishes. Further, its industrial coatings segment offers products including coil and extrusion coatings, wood finishes, packaging coatings, and adhesives. The company owns more than 3,100 patents and has robust research and development capabilities which is evident from the fact that it has spent around USD 1.33 billion on research and development in last five years and possess five R&D centers. The brand portfolio offered by the company includes Dulux, Sikkens, International and Interpon and has a strong geographical presence in around 150 countries.
58 interactive charts drawn from the 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market dataset — market size, each segment breakdown, and every region and country by segment. Open one to read its full data table and download it.
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market By Region
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market By Downstream Product
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market By Purity
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market — North America by Country
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market — North America by Purity
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market — North America by Downstream Product
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market — U.S. by Purity
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market — U.S. by Downstream Product
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market — Canada by Purity
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market — Canada by Downstream Product
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market — Mexico by Purity
Global 2-Chloro-1-(1-Chlorocyclopropyl)ethanone Market — Mexico by Downstream Product
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and forecast (2022–2032, USD Million)
Market Size (USD Million)
